

P&T Motion History Statins

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<p><u>Individual Statins</u> atorvastatin fluvastatin fluvastatin ER lovastatin lovastatin ER pitavastatin pravastatin rosuvastatin simvastatin</p>	<p>After considering the evidence of safety, efficacy and special populations, I move that the following statins are safe and efficacious: pitavastatin, atorvastatin, fluvastatin, fluvastatin ER, lovastatin, lovastatin ER, pravastatin, rosuvastatin, and simvastatin (all forms) and can be subjected to therapeutic interchange in the Washington Preferred Drug List. The PDL must include at least one high potency option (atorvastatin and/or rosuvastatin) and the PDL must include pravastatin as an alternative with minimal cytochrome P450 drug interactions.</p>	<p>April 18, 2108</p>	<p>Yes Brown Sanderson</p>	<p>Figuroa Storhaug</p>	<p>Passed unanimous</p>
<p><u>Combination Products</u> atorvastatin/ ezetimibe* lovastatin/ niacin ER simvastatin/ ezetimibe simvastatin/ niacin ER</p>	<p>I move to not include the combination products as part of the statin drug class on the PDL.</p> <p>Motion: Chew 2nd: Johnson</p>				

Bold = new this update

Grey = not reviewed, not eligible to be preferred on PDL

*= product is discontinued

4/19/2018